Peptide Industry News: FDA Approvals, Clinical Trials & Market Updates

This hub page indexes all 14 news articles on ChemVerify. These articles track the most significant developments in the peptide industry — FDA approvals, clinical trial milestones, market shifts, and regulatory changes that affect laboratory researchers.

News articles are time-sensitive and reflect the state of the industry at their publication date. They are updated when material changes occur.

• Orforglipron FDA Approval April 2026: First Oral GLP-1 Without Food Restrictions → /learn/orforglipron-fda-approval-april-2026 — First non-peptide small-molecule oral GLP-1 receptor agonist approved
• ICOTYDE (Icotrokinra): First Targeted Oral Peptide for Plaque Psoriasis — FDA Approved → /learn/icotyde-icotrokinra-fda-approved-oral-peptide-plaque-psoriasis — First oral peptide blocking IL-23 receptor
• RFK Jr. Signals Reversal of Peptide Ban: 14 of 19 Restricted Compounds May Return → /learn/rfk-jr-signals-reversal-of-peptide-ban-14-of-19-restricted-compounds-may-return — Potential reversal of FDA peptide restrictions
• Medicare GLP-1 Bridge Program: $50/Month Coverage Starting July 2026 → /learn/medicare-glp1-bridge-program-50-month-coverage-july-2026 — First-ever Medicare coverage for obesity medications
• Peptide Sciences Shuts Down: What the Largest US Gray-Market Vendor's Closure Means → /learn/peptide-sciences-shutdown-gray-market-impact — Regulatory forces, quality verification gaps, market consolidation

• Retatrutide Phase 3 Results: The Triple-Agonist Achieving 28.7% Weight Loss → /learn/retatrutide-phase-3-results-triple-agonist-weight-loss — TRIUMPH-4 trial data, GLP-1/GIP/glucagon triple agonist
• Semaglutide SELECT Trial: 20% Cardiovascular Risk Reduction in Patients with Obesity → /learn/semaglutide-select-trial-cardiovascular-outcomes-2024 — Largest CV outcome study of a GLP-1 RA in non-diabetic obesity
• GLP-1 Receptor Agonists in Neurological Research: 2026 Evidence Review → /learn/glp-1-neurological-research-2026 — Synaptogenesis amplification 7x greater than BDNF alone

• Pinnacle Medicines Raises $89M for Next-Generation Oral Peptides → /learn/pinnacle-medicines-raises-89m-oral-peptides — Series B financing, lead asthma/COPD program entering human testing
• Unnatural Products and Novartis: A $1.7 Billion Deal for Synthetic Macrocyclic Peptides → /learn/unnatural-products-novartis-1-7-billion-macrocyclic-peptides-deal — CycloSEL platform, cardiovascular targets

• Global Peptide Synthesis Market 2026: $1.9B Industry Report → /learn/peptide-market-2026-report — Projected to hit $2.59B by 2031, 10.1M peptide searches in January 2026

• BPC-157: First Human Intravenous Safety Data Published in 2025 Pilot Study → /learn/bpc-157-first-human-iv-safety-pilot-2025 — First published human safety data for IV BPC-157
• Longevity Peptides: An Evidence-Based Assessment of Current Claims → /learn/longevity-peptides-evidence-based-assessment-2025 — BPC-157, MOTS-c, Epitalon claims vs clinical data
• MOTS-c: Mitochondrial Peptide Research and the Longevity Evidence Gap → /learn/mots-c-mitochondrial-peptide-longevity-evidence-2025 — Preclinical data, CB4211 pipeline, community claims disconnect